Naltrexone/Bupropion
Phase 3Small molecule
Novo NordiskNaltrexone/Bupropion is one of 42 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
2
Indications
8
Total Trials
2
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Naltrexone/Bupropion
Novo NordiskPhase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity4 trials
Anti-obesity Pharmacotherapy and Inflammation
Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled
Metformin1 trial
Breast Cancer1 trial
Gastrectomy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Naltrexone/Bupropion. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company